Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BUFFALO, N.Y., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced the publication in Science Magazine of the first structural and biophysical study of the...
-
BUFFALO, NY--(Marketwire - Feb 6, 2012) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 14th Annual BIO CEO and Investor Conference,...
-
BUFFALO, NY--(Marketwire - Jan 24, 2012) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company has made a number of changes in corporate management responsibilities to maximize...
-
BUFFALO, NY--(Marketwire - Jan 17, 2012) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the online publication of a manuscript describing the radioprotective and radiomitigating...
-
BUFFALO, NY--(Marketwire - Jan 11, 2012) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at Noble Financial Capital Markets' Eighth Annual Equity...
-
BUFFALO, NY--(Marketwire - Dec 1, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 4th Annual LD MICRO Growth Conference, December 7-8,...
-
BUFFALO, NY--(Marketwire - Nov 1, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will host a quarterly update conference call at 10:00 a.m. ET on November 10, 2011. ...
-
BUFFALO, NY--(Marketwire - Oct 24, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced pre-publication of a study demonstrating CBLB502's ability to both protect from local radiation...
-
BUFFALO, NY--(Marketwire - Oct 19, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a new Investigational New Drug (IND) application for clinical testing of CBLB502 in a variety...
-
BUFFALO, NY--(Marketwire - Oct 3, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a study demonstrating CBLB502's ability to inhibit acute renal ischemic failure was published...